1. Home
  2. MRKR vs HHS Comparison

MRKR vs HHS Comparison

Compare MRKR & HHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Marker Therapeutics Inc.

MRKR

Marker Therapeutics Inc.

HOLD

Current Price

$1.61

Market Cap

22.5M

Sector

Health Care

ML Signal

HOLD

Logo Harte-Hanks Inc.

HHS

Harte-Hanks Inc.

HOLD

Current Price

$2.28

Market Cap

21.2M

ML Signal

HOLD

Company Overview

Basic Information
Metric
MRKR
HHS
Founded
1999
1923
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Advertising
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
22.5M
21.2M
IPO Year
2010
1994

Fundamental Metrics

Financial Performance
Metric
MRKR
HHS
Price
$1.61
$2.28
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$10.00
N/A
AVG Volume (30 Days)
64.6K
2.8K
Earning Date
05-14-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
33.61
97.35
EPS
N/A
N/A
Revenue
N/A
$159,570,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$936.27
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.81
$2.07
52 Week High
$4.07
$4.32

Technical Indicators

Market Signals
Indicator
MRKR
HHS
Relative Strength Index (RSI) 66.31 49.46
Support Level $1.35 $2.28
Resistance Level $1.69 $2.94
Average True Range (ATR) 0.08 0.10
MACD 0.03 0.01
Stochastic Oscillator 78.51 72.37

Price Performance

Historical Comparison
MRKR
HHS

About MRKR Marker Therapeutics Inc.

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).

About HHS Harte-Hanks Inc.

Harte-Hanks Inc is a customer experience company. The Company operates three business segments: Marketing Services; Customer Care; and Fulfillment & Logistics Services. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.

Share on Social Networks: